Huya, Eisai deal

Huya granted Eisai exclusive rights to develop and commercialize HBI-8000 for cancer indications in Japan, South Korea, Thailand, Malaysia, Indonesia, the Philippines, Vietnam and Singapore. Huya will complete development of the small molecule histone deacetylase (HDAC) inhibitor for non-Hodgkin’s lymphoma (NHL) in Japan, and Eisai will develop the product for solid tumor indications. Huya has exclusive rights from Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, China) to develop and commercialize HBI-8000 outside of China and Taiwan to treat cancer. Gold NanoTech Inc. (Taipei, Taiwan) holds exclusive rights in Taiwan. ...